Denali Therapeutics Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $205.3M | $175.0M | $127.1M | $218.0M | $293.5M | $507.1M | $79.4M | $77.1M |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $900.7M | $864.4M | $1.06B | $1.37B | $897.2M | $1.50B | $430.0M | $480.8M |
| Property, Plant & Equipment | $52.4M | $55.2M | $45.6M | $44.1M | $38.9M | $40.8M | $46.7M | $25.2M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $1.14B | $1.37B | $1.15B | $1.46B | $1.40B | $1.60B | $553.2M | $662.0M |
| Liabilities | ||||||||
| Accounts Payable | $3.3M | $11.1M | $9.5M | $2.8M | $4.8M | $1.1M | $2.6M | $1.9M |
| Total Current Liabilities | $98.4M | $102.2M | $78.0M | $363.9M | $378.2M | $71.7M | $45.3M | $32.8M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $131.1M | $144.5M | $123.0M | $417.8M | $441.9M | $453.7M | $158.3M | $115.1M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-2.05B | $-1.54B | $-1.12B | $-971.0M | $-645.0M | $-354.4M | $-425.6M | $-227.9M |
| Total Stockholders' Equity | $1.01B | $1.23B | $1.03B | $1.04B | $962.3M | $1.15B | $394.9M | $546.8M |